Items in cart [1] Questions? Call 888-624-8373

PAPERBACK list:$33.75 Web:$30.38 add to cart Rights & Permissions Free PDF Access Free Resources Sign in to download PDF book and chapters PDF EXECUTIVE SUMMARY Display this book on your site! Related Titles Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients) From Cancer Patient to Cancer Survivor: Lost in Transition Other Related Titles Medicare Coverage of Routine Screening for Thyroid Dysfunction (2003) Board on Health Care Services (HCS) Institute of Medicine (IOM) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 73   E-mail  Facebook  Digg  Stumble  Twitter More The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. APPENDIX A Workshop on Screening for Thyroid Dysfunction OCTOBER 31, 2002, IRVINE, CALIFORNIA 8:00 a.m. - Screening for Thyroid Disease - Systematic Evidence Review Mark Helfand, M.D., M.P.H. Oregon Health and Science University 8:40 a.m. - Thyroid Disease, Osteoporosis and Lipids in the Elderly Douglas C. Bauer, M.D. University of California - San Francisco 9:20 a.m. - Subclinical Thyroid Disease in a Screening Population E. Chester Ridgway, M.D. University of Colorado Health Sciences Center 10:00 a.m. - Break 10:30 a.m. - Thyroid Disease in the New Mexico Elder Health Survey Robert D. Lindeman, M.D. University of New Mexico Health Sciences Center 11:10 a.m. – Studies of Lipids and Thyroid Dysfunction Marc Stone, M.D. The Institute of Medicine Page 73 Front Matter (R1-R14) Summary (1-6) 1. Introduction (7-13) 2. Pathophysiology and Diagnosis of Thyroid Disease (14-20) 3. Prevalence and Consequences of Thyroid Dysfunction (21-31) 4. Screening for Thyroid Dysfunction (32-43) 5. The Cost of Coverage (44-68) 6. Conclusions and Recommendations (69-72) Appendix A: Workshop on Screening for Thyroid Dysfunction (73-74) Appendix B: Screening for Thyroid Disease: Systematic Evidence Review (75-113) Appendix C: Diagnoses Currently Covered by Medicare for Serum TSH Testing (114-118) Appendix D: Committee Biographies (119-121)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 73
APPENDIX A Workshop on Screening for Thyroid Dysfunction OCTOBER 31, 2002, IRVINE, CALIFORNIA 8:00 a.m. - Screening for Thyroid Disease - Systematic Evidence Review Mark Helfand, M.D., M.P.H. Oregon Health and Science University 8:40 a.m. - Thyroid Disease, Osteoporosis and Lipids in the Elderly Douglas C. Bauer, M.D. University of California - San Francisco 9:20 a.m. - Subclinical Thyroid Disease in a Screening Population E. Chester Ridgway, M.D. University of Colorado Health Sciences Center 10:00 a.m. - Break 10:30 a.m. - Thyroid Disease in the New Mexico Elder Health Survey Robert D. Lindeman, M.D. University of New Mexico Health Sciences Center 11:10 a.m. – Studies of Lipids and Thyroid Dysfunction Marc Stone, M.D. The Institute of Medicine

OCR for page 74
11:50 a.m. - Medicare Experience with Screening and Preventive Services Benefits A. Marshall McBean, M.Sc., M.D. University of Minnesota School of Public Health 12:30 p.m. - Lunch 1:30 p.m. - TSH Screening for Medicare - Results from a Cost-Effectiveness Model Neil Powe, M.D., M.P.H., M.B.A. Johns Hopkins School of Public Health Mark Danese, Ph.D. Amgen, Inc. 2:10 p.m. - Roundtable Discussion 3:00 p.m. - Break 3:20 p.m. - Roundtable Discussion (Continued) 4:30 p.m. - Adjournment

Representative terms from entire chapter:

sciences center